Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases that threaten vision. Its lead candidate, TH103, is an engineered anti-VEGF protein designed to block vascular endothelial growth factor, a key driver of abnormal blood vessel growth and leakage in the eye.

The company is studying TH103 in conditions such as neovascular (wet) age-related macular degeneration and diabetic macular edema, with the goal of providing longer-lasting effect and less frequent eye injections than current anti-VEGF therapies.

Kalaris became a Nasdaq-listed company in 2025 through a merger with AlloVir, a previously public biotechnology company.